Evidence map›Paper›PMID 19546879›Full record

ArticleImmunology and cell biology

Why is effective treatment of asthma so difficult? An integrated systems biology hypothesis of asthma.

Norbert F Voelkel, Sarah Spiegel

Open access · greenAbstract read
In one paragraph

Article in Immunology and cell biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Norbert F VoelkelDepartment of Biochemistry and Molecular Biology, Victorial Johnson Center for Obstructive Pulmonary Disease Research, Virginia Commonwealth University, Richmond, 23298, USA. nvoelkel@mcvh-vcu.edu
Sarah Spiegel
Virginia Commonwealth University · US

Funding

The Effect of Lyn Deficiency on Mast Cell Activation and Inflammatory Disease ProU19AI077435 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI CONRAD, DANIEL H · 2008 to 2012
$7.7M
Sphingosine Kinases in Cancer Cell SignalingR01CA061774 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SPIEGEL, SARAH · 1994 to 2015
$3.8M
Targeting sphingosine kinases in FceRI-mediated allergic responsesR01AI050094 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI SPIEGEL, SARAH · 2002 to 2012
$2.9M
NCI NIH HHS R01 CA061774NIAID NIH HHS R01 AI050094NIAID NIH HHS U19 AI077435
6 · The paper itself

Abstract

A hypothesis is presented that asthma is not only an airway disease, but that the disease involves the entire lung, and that the chronicity of asthma and asthma exacerbations can perhaps be explained if one considers asthma as a systemic disease. Increased lung-not only airway-vascularity may be the result of the action of angiogenesis factors, such as vascular endothelial growth factor (VEGF) and sphingosine-1-phosphate (S1P). A bone-marrow lung axis can be postulated as one element of the systemic nature of the asthma syndrome, in which the inflamed lung emits chemotactic signals, which the bone marrow responds to by releasing cells that contribute to lung angiogenesis. A molecular model of the pathobiology of asthma can be built by connecting hypoxia-inducible transcription factor-1 alpha, VEGF S1P, and bone-marrow precursor cell mobilization and acknowledging that angiogenesis is part of the inflammatory response.

Indexed as

AnimalsAsthmaBone MarrowHumansLysophospholipidsNeovascularization, PathologicSphingosineSystems BiologyVascular Endothelial Growth Factor ALysophospholipidsSphingosinesphingosine 1-phosphateVascular Endothelial Growth Factor A

Identifiers

PMID19546879
PMCPMC2850593
OpenAlexW2061227929

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.